GordonMD Global Investments LP's Form 4/A amendment
AmendedPyxis Oncology, Inc.PYXS · filed Oct 9, 2026
- Accession no.
- 0000919574-26-006815
- Filed
- Oct 9, 2026, 2:39 PM ET
- Trade date
- Oct 1, 2026
- Filing delay
- 8 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Oct 2, 2026
This filing lists 1 derivative transaction. It carries over 1 transaction from the original filing that it did not restate. It was filed 8 days after the trade.
This amendment restates part of 0000919574-26-006609 (filed Oct 2, 2026). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| GordonMD Global Investments LPCIK 0002039349 | 10% Owner |
| GordonMD Long Biased GP LLCCIK 0002103778 | 10% Owner |
| GordonMD Long Biased Master Fund LPCIK 0002103789 | 10% Owner |
| Gordon Craig DCIK 0002103811 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Common Stock | PPurchaseAcquired | +7,172,000 | –F2 | – | 7,172,000 | Indirect |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0000919574-26-006609 (filed Oct 2, 2026).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Common Stock, par value $0.001 per share ("Common Stock") | PPurchaseAcquired | +5,517,000 | –F2 | – | 15,541,909 | Indirect |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
- F2
The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90.
Referenced by the price of 1 transaction in Table II.
- F3
Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant.
- F4
The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the "Charter Amendment") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the "Charter Amendment Effective Date").
- F5
The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma.
Remarks
This Form 4/A is being filed to correct the number of Common Stock Purchase Warrant reported in the Form 4 filed by the Reporting Persons with the Securities and Exchange Commission on October 2, 2026.